Vital Signs - Ocular Drug Delivery: Expanding the Field of Vision

 

Regular Price: USD 1,500.00

Special Price USD 1,050.00

30% OFF

* Required Fields

Regular Price: USD 1,500.00

Special Price USD 1,050.00

PAY BY INVOICE

Be the first to review this product

This issue of Vital Signs, released on March 30, 2009, provides a strategic overview of selected new technology approaches and opportunities in ocular drug delivery and ophthalmic pharmaceuticals. Additionally, a company spotlight is provided for Inotek Pharmaceuticals, a company developing focused on developing products from its research into the regulation of cellular responses to tissue damaging conditions such as hypoxia, ischemia-reperfusion, diabetes, glaucoma, and angiogenic dysregulation. Reimbursement and regulatory news from the FDA is also provided for the week of March 16, 2009.

Table of Contents

Vital Signs - Ocular Drug Delivery: Expanding the Field of VisionVital Signs: 30 March 2009This week's issue:




Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.